Patents by Inventor David Andre Baptiste Maussang Detaille

David Andre Baptiste Maussang Detaille has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240182587
    Abstract: The invention relates to the field of antibodies. In particular it relates to the field of therapeutic (human) antibodies for the treatment of ErbB-2/ErbB-3 positive cells. More in particular it relates to treating of cells comprising an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location.
    Type: Application
    Filed: February 21, 2024
    Publication date: June 6, 2024
    Inventors: Mark THROSBY, Cecilia Anna Wihelmina GEUIJEN, David Andre Baptiste MAUSSANG-DETAILLE, Ton LOGTENBERG
  • Patent number: 11780925
    Abstract: The invention relates to the field of antibodies. In particular it relates to the field of therapeutic (human) antibodies for the treatment of ErbB-2/ErbB-3 positive cells. More in particular it relates to treating of cells comprising an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: October 10, 2023
    Inventors: Mark Throsby, Cecilia Anna Wilhelmina Geuijen, David Andre Baptiste Maussang-Detaille, Ton Logtenberg
  • Publication number: 20210206875
    Abstract: The invention relates among others to antibodies comprising a first antigen-binding site that binds ErbB-2 and a second antigen-binding site that binds ErbB-3. The antibodies can typically reduce a ligand-induced receptor function of ErbB-3 on a ErbB-2 and ErbB-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an ErbB-2, ErbB-3 or ErbB-2/3 positive tumor.
    Type: Application
    Filed: April 3, 2018
    Publication date: July 8, 2021
    Inventors: Mark THROSBY, Cecilia Anna Wilhelmina GEUIJEN, David Andre Baptiste MAUSSANG-DETAILLE, Ton LOGTENBERG
  • Publication number: 20210054096
    Abstract: The invention relates to methods of treating of subject that has breast cancer or is at risk of having said cancer, comprising administering to the subject in need thereof a combination of a therapeutically effective amount of an ErbB-2/ErbB-3 bispecific antibody and a therapeutically effective amount of an endocrine therapy drug, wherein the bispecific antibody has an antigen binding site that can bind an extra-cellular part of ErbB-2 and an antigen binding site that can bind an extra-cellular part of ErbB-3; and to means for said method.
    Type: Application
    Filed: May 17, 2018
    Publication date: February 25, 2021
    Inventors: David Andre Baptiste Maussang-Detaille, Cecilia Anna Wilhelmina Geuijen
  • Publication number: 20200291130
    Abstract: The invention relates to the field of antibodies. In particular it relates to the field of therapeutic (human) antibodies for the treatment of ErbB-2/ErbB-3 positive tumor. More in particular it relates to treating tumors with a high ErbB-2/ErbB-3 cell-surface receptor ratio. Also encompassed are methods for treating patients not previously treated with an ErbB-2 specific therapy or with an ErbB-3 specific therapy.
    Type: Application
    Filed: April 3, 2018
    Publication date: September 17, 2020
    Inventors: Mark THROSBY, Cecillia Anna Wilhelmina GEUIJEN, David Andre Baptiste MAUSSANG-DETAILLE, Ton LOGTENBERG
  • Publication number: 20200102393
    Abstract: The invention relates to the field of antibodies. In particular it relates to the field of therapeutic (human) antibodies, for the treatment of ErbB-2/ErbB-3 positive cells. More in particular it relates to treating of cells comprising an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location.
    Type: Application
    Filed: April 3, 2018
    Publication date: April 2, 2020
    Inventors: Mark THROSBY, Cecilia Anna Wilhelmina GEUIJEN, David Andre Baptiste MAUSSANG-DETAILLE, Ton LOGTENBERG
  • Publication number: 20180355048
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumour growth.
    Type: Application
    Filed: May 3, 2018
    Publication date: December 13, 2018
    Applicant: Ablynx N.V.
    Inventors: Francis Descamps, David Andre Baptiste Maussang-Detaille, Maarten Van Roy, Maria Gonzalez Pajuelo, Regorius Leurs, Pascal Gerard Marchiers, Martine Smit, Catelijne Stortelers, Philippe Van Rompaey, Peter Vanlandschoot
  • Patent number: 9994639
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumor growth.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: June 12, 2018
    Assignee: Ablynx N.V.
    Inventors: Francis Descamps, David Andre Baptiste Maussang-Detaille, Maarten Van Roy, Maria Gonzalez Pajuelo, Regorius Leurs, Pascal Gerard Merchiers, Martine Smit, Catelijne Stortelers, Philippe Van Rompaey, Peter Vanlandschoot
  • Patent number: 9758584
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: September 12, 2017
    Assignee: Ablynx N.V.
    Inventors: Francis Descamps, Maria Gonzalez, Pascal Gerard Merchiers, Catelijne Stortelers, Peter Vanlandschoot, Philippe Van Rompaey, Martine Smit, Regorius Leurs, David Andre Baptiste Maussang-Detaille
  • Patent number: 9512236
    Abstract: The present invention relates to amino acid sequences that are directed against G-protein coupled receptors (GPCRs), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: December 6, 2016
    Assignee: Ablynx N.V.
    Inventors: Hendrik Adams, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Christophe Blanchetot, Martine Smit, Regorius Leurs, Sven Jähnichen, Peter Vanlandschoot, Francis Descamps, Maria Gonzalez Pajuelo, Pascal Gerard Merchiers, Catelijne Stortelers, Philippe Van Rompaey, David Andre Baptiste Maussang-Detaille, Maarten Van Roy
  • Publication number: 20150158948
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumour growth.
    Type: Application
    Filed: March 28, 2012
    Publication date: June 11, 2015
    Inventors: Francis Descamps, David André Baptiste Maussang-Detaille, Maarten Van Roy, Regorius Leurs, Maria Gonzalez Pajuelo, Pascal Gerard Merchiers, Martine Smit, Catelijne Stortelers, Philippe Van Rompaey, Peter Vanlandschoot
  • Publication number: 20150110796
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 23, 2015
    Applicant: ABLYNX N.V.
    Inventors: FRANCIS DESCAMPS, MARIA GONZALEZ PAJUELO, PASCAL GERARD MERCHIERS, CATELIJNE STORTELERS, PETER VANLANDSCHOOT, PHILIPPE VAN ROMPAEY, MARTINE SMIT, REGORIUS LEURS, DAVID ANDRE BAPTISTE MAUSSANG-DETAILLE
  • Patent number: 8937164
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: January 20, 2015
    Assignee: Ablynx N.V.
    Inventors: Francis Descamps, Maria Gonzalez Pajuelo, Pascal Gerard Merchiers, Catelijne Stortelers, Peter Vanlandschoot, Philippe Van Rompaey, Martine Smit, Regorius Leurs, David Andre Baptiste Maussang Detaille
  • Publication number: 20140227270
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumour growth.
    Type: Application
    Filed: March 28, 2012
    Publication date: August 14, 2014
    Inventors: Francis Descamps, David André Baptiste Maussang-Detaille, Maarten Van Roy, Regorius Leurs, Maria Gonzalez Pajuelo, Pascal Gerard Merchiers, Martine Smit, Catelijne Stortelers, Philippe Van Rompaey, Peter Vanlandschoot
  • Publication number: 20140178390
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumour growth.
    Type: Application
    Filed: July 9, 2013
    Publication date: June 26, 2014
    Applicant: Ablynx N.V.
    Inventors: Francis Descamps, David Andre Baptiste Maussang-Detaille, Maarten Van Roy, Maria Gonzalez Pajuelo, Regorius Leurs, Pascal Gerard Merchiers, Martine Smit, Catelijne Stortelers, Philippe Van Rompaey, Peter Vanlandschoot
  • Publication number: 20110262438
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.
    Type: Application
    Filed: March 28, 2011
    Publication date: October 27, 2011
    Applicant: Ablynx N.V.
    Inventors: Francis Descamps, Maria Gonzalez Pajuelo, Pascal Gerard Merchiers, Catelijne Stortelers, Peter Vanlandschoot, Philippe Van Rompaey, Martine Smit, Regorius Leurs, David Andre Baptiste Maussang Detaille